1. MiR-143 Inhibits Osteoclastogenesis by Targeting RANK and NF-κB and MAPK Signaling Pathways
   Xianfeng He et al, 2020, Current Molecular Pharmacology CrossRef
2. Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma
   François Lamoureux et al, 2008, Molecular Cancer Therapeutics CrossRef
3. Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma
   Francois Lamoureux et al, 2009, Cancer Research CrossRef
4. The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases
   Benjamin Navet et al, 2018, Cancers CrossRef
5. Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption
   François Lamoureux et al, 2007, Cancer Research CrossRef
6. Osteosarcoma and Metastasis Associated Bone Degradation—A Tale of Osteoclast and Malignant Cell Cooperativity
   Kirstine Sandal Nørregaard et al, 2021, International Journal of Molecular Sciences CrossRef